Asystole Induced by Edrophonium Following Beta Blockade
Neurol 57:739, Okun,M.S.,et al, 2001
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Syncope and Presyncope Associated with Probable Adverse Drug Reactions
Arch Int Med 150:2309-2312, Hanlon,J.T.,et al, 1990
Disorders of Neuromuscular Transmission Caused by Drugs
NEJM 301:409-413, Argov,Z.,et al, 1979
Neurovascular Complications of Iatrogenic Fusarium solani Meningitis
NEJM 390:522-529, Strong, N.,et al, 2024
Blook Transfusion and Brain Amyloidosis, Should We Be Worried?
JAMA 330:921-922, Greenberg,S.M., 2023
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12 Deficiency
JAMA 310:2435-2442, Lam, J.R.,et al, 2013
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Use of Antihypertensives and the Risk of Parkinson Disease
Neurol 70:1438-1444, Becker,C.,et al, 2008
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Life-Threatening Acute Pancreatitis Associated with Interferon Beta-1a Treatment in Multiple Sclerosis
Neurol 65:170-171, Midgard,R.,et al, 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005